Jeffrey Adam Novack - 03 Feb 2025 Form 4 Insider Report for CareDx, Inc. (CDNA)

Signature
/s/ Jeffrey Adam Novack
Issuer symbol
CDNA
Transactions as of
03 Feb 2025
Net transactions value
-$129,589
Form type
4
Filing time
05 Feb 2025, 16:30:43 UTC
Previous filing
06 Dec 2024
Next filing
25 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDNA Common Stock Tax liability $47,759 -2,048 -1.9% $23.32 108,189 03 Feb 2025 Direct F1
transaction CDNA Common Stock Sale $81,829 -3,512 -3.2% $23.30 104,677 04 Feb 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F2 The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 19, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.1000 to $23.7300, inclusive. The Reporting Person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.